Jump to content
RemedySpot.com

How did XMRV enter the Human Population?

Rate this topic


Recommended Posts

Posted

For private members the Provisional PDF file is attached;

others can download the full text via the abstract site,

because the mentioned URL doesn't work.

http://www.frontiersin.org/virology/10.3389/fmicb.2010.00147/abstract

~jan van roijen

````

frontiers

IN VIROLOGY

Of mice and men:

on the origin of XMRV

Antoinette Cornelia Van der kuyl,

n Cornelissen and Ben Berkhout

Journal Name: Frontiers in Microbiology

ISSN: 1664-302X

Article type: Perspective Article

Received on: 20 Sep 2010

Accepted on: 26 Dec 2010

Provisional PDF published on: 26 Dec 2010

Frontiers website link: www.frontiersin.org

Citation: Van der kuyl AC, Cornelissen M and Berkhout B

(2010) Of mice and men: on the origin of XMRV. Front.

Microbio. 1:147. - doi:10.3389/fmicb.2010.00147

http://www.frontiersin.org/virology/10.3389/fmicb.2010.00147/abstract

s=1161 & name=virology & ART_DOI=10.3389/fmicb.2010.00147

(If clicking on the link doesn't work, try copying and pasting it

into your browser.)

Perspective

Of mice and men:

on the origin of XMRV

Running title:

How did XMRV enter the

human population?

Antoinette C. van der Kuyl, n Cornelissen

and Ben Berkhout

Laboratory of Experimental Virology, Department of Medical

Microbiology, Center for Infection

and Immunity Amsterdam (CINIMA), Academic Medical Center,

University of Amsterdam,

Meibergdreef 15, 1105 AZ Amsterdam, The Netherlands

Abstract

The novel human retrovirus XMRV (xenotropic murine leukemia

virus-related virus) is arguably the most controversial virus of

this moment.

After its original discovery in prostate cancer tissue from North

American patients, it was subsequently detected in individuals

with chronic fatigue syndrome (CFS) from the same continent.

However, most other research groups, mainly from Europe,

reported negative results.

The positive results could possibly be attributed to

contamination with mouse products in a number of cases, as

XMRV is nearly identical in nucleotide sequence to endogenous

retroviruses in the mouse genome.

But the detection of integrated XMRV proviruses in prostate

cancer tissue proves it to be a genuine virus that replicates in

human cells, leaving the question: how did XMRV enter the

human population?

We will discuss two possible routes: either via direct virus

transmission from mouse to human, as repeatedly seen for

e.g. hantaviruses, or via the use of mouse-related products by

humans, including vaccines.

We hypothesize that mouse cells or human cell lines used for

vaccine production could have been contaminated with a

replicating variant of the XMRV precursors encoded by the

mouse genome.

Introduction

The xenotropic murine leukemia virus-related virus (XMRV) is

undoubtedly the most controversial human virus since its first

detection in human samples in 2006 [1].

XMRV infection still lacks a firm disease association, although

the virus was originally isolated from prostate cancer tissue

and subsequently detected in the blood of American patients

with chronic fatigue syndrome (CFS) [2], and in the respiratory

tract of patients with or without a respiratory tract infection

[3].

However, irregular XMRV detection [2-7] suggests that it is not

likely to be a major causal factor. First, we do not know

whether the biological reservoir has been investigated thus

far, as most studies focused exclusively on blood or prostate

tissue (summarized in Table 1).

Second, some pathogenic retroviruses do not cause much of a

viraemia, and experimental infection of macaques suggests

that this is also the case for XMRV [8].

In these monkeys, virus inoculation resulted in a low transient

plasma viraemia, followed by a wide dissemination of

replicating virus into various organs including spleen, lymph

nodes and gastrointestinal tract.

Third, sequence variation may exist, but such variant virus

strains could be missed by the PCR primers used.

Whether or not the virus causes disease in humans (reviewed

extensively by Silverman et al. [9], see also comments by

Coffin and Stoye [10], by Kearney and Maldarelli [11], by

Kaiser [12], and the cautionary note by Weiss [13]), and how

and when XMRV entered the human population - as the first

gammaretrovirus to do so - remains unclear.

To add to the ongoing discussion, we would like to propose an

alternative possible source for XMRV, human vaccines or other

biological products that were produced in murine cells.

How did XMRV enter the human population? One of the most

striking aspects of XMRV biology is the high sequence

similarity to mouse chromosal sequences that encode

endogenous retroviruses.

Initially, this raised the speculation that contamination with

mouse DNA could explain the presence of XMRV in human

samples.

However, the absence of other mouse-derived sequences,

combined with the ease of infection of human cells with XMRV

in vitro [14], and the detection of integrated proviruses in

prostate cancer tissues [15,16] indicated that laboratory

contamination with mouse products is not a likely explanation

for the origin of XMRV, at least for some of these studies.

If contamination does not provide an explanation, where does

the virus come from and how did it end up in humans?

Direct transmission of viruses from wild rodents to humans is

not uncommon, e.g. rodent hantaviruses and arenaviruses

spread through excrement via aerosols and are able to infect

nonrodent species, including humans [17-19].

Transmission of xenotropic murine leukemia viruses (XMLV's)

to humans is possible as human cells do express the XPR1

protein that is able to function as receptor for xenotropic and

polytropic murine retroviruses.

The human XPR1 receptor protein shows a preference for

xenotropic retroviruses, but is also able to mediate infection of

polytropic murine leukemia retroviruses (P-MLV's) [20].

Classical laboratory mice strains are hybrids between Mus

musculus musculus, M. m. domesticus and M. m. castaneus,

with around two-thirds of the genome coming from M. m.

domesticus [21].

X-MLV's cannot (re-)infect most of the laboratory mouse

strains due to polymorphisms in the XPR1 protein that disable

xenotropic virus entry [22].

Interestingly, the XPR1 genotype that prohibits X-MLV entry

was not found in wild-caught M. m. domesticus, suggesting

that it is a rare allele [23]. Indeed, extensive screening

identified 7 strains of laboratory mice strains containing a

permissive allele, of which at least three were susceptible to

XMLV and XMRV in cell culture [23].

In addition, the F/St mouse strain also produced infectious

XMLV together with a lifelong viraemia [23]. Many feral mice

species, e.g. M. dunni and M. spretus, are also susceptible to

infection with X-MLV's [20,22,24].

Evidence on M. m. castaneus is conflicting, with some

reporting a non-functional and others a susceptible XPR1

phenotype [22,25]. The ability of XPR1 to function as a

receptor for xenotropic viruses was found to depend on the

identity of two amino acid residues [22].

The origin of XMRV?

Every mouse genome contains multiple copies of endogenous

MLV and has thus the capacity to express viral RNA and

possibly viral particles.

Endogenous MLV transcription has been described for many

tissues and several mouse strains. It remains unclear if and

when virus particles are generated and whether these particles

are actually excreted.

Zoonotic transmission of these viruses could have occurred in

the many million years that mice and men have shared the

same environment.

But current XMRV sequences isolated from human samples do

closely mimic mouse genomic sequences, thus suggesting a

low number of replication cycles since zoonotic transmission,

which is thus likely to have occurred recently.

The mutation rate of MLV's is not different from other

retroviruses [26] (although its replication rate may be low),

implying that if the transmission had taken place a long time

ago, more nucleotide substitutions should have become fixed.

Phylogenetic sequence analysis, however, revealed very short

branches for XMRV and the mouse xMERV sequences on

chromosomes 7 and 9, indicating that very few mutations have

occurred since transmission [1,3,4].

In addition to the loci on chromosomes 7 and 9, a BLAST

search using the NCBI sequence database

(http://blast.ncbi.nlm.nih.gov/Blast.cgi) retrieves loci on

mouse chromosomes 4, 11 and 12 with a much higher

(98-100%) sequence identity to XMRV-gag nucleotide

sequences (e.g. GenBank accession numbers AC124739,

AY349138, and AL627314).

Blasting whole genome XMRV sequences recovers very similar

sequences with large stretches of sequence identity on mouse

chromosomes 4, 5, 13 and Y, especially for the 3' end of the

XMRV genome.

These results suggest that the genome of human XMRV is

present, albeit in two parts, in the mouse genome with

effectively no nucleotide changes. Even in slowly evolving

retroviruses like foamy viruses, 100% sequence identity is only

seen in animals with close contact or humans that have been

bitten by an infected primate, suggestive of direct

transmission, while intraspecies variation is generally around

85-95% for the pol gene [27-29].

A recently described locus [23] on chromosome 1 of M.

musculus (GenBank accession number AC115959) contains a

provirus that is 92% homologous to XMRV from the 22Rv1 cell

line (GenBank accession number FN692043) over its complete

genome length. This provirus, Bxv1, is mainly found in

Japanese M. molossinus (a natural hybrid of M. castaneus and

M. musculus) and is highly expressed in some laboratory

mouse strains [23].

However, the Bxv1 provirus is less likely to be the source of

XMRV, as its similarity to XMRV is much lower than that of

other murine loci.

XMRV is a novel recombinant retrovirus

XMRV is actually a recombinant virus, resembling

polytropic-endogenous sequences for the 5' half up to

approximately the middle of the pol gene and

xenotropic-endogenous sequences for the 3' half of the

genome, which includes the env gene (see: [30]).

This recombination event is likely to have occurred in the

mouse before transmission to humans. At least one

recombinant provirus, Bxv1, is already found in the M.

musculus genome [23]. This locus is heterogeneous in

subspecies of M. musculus, suggesting that it represents a

recent integration.

Recombination rates are high for all retroviruses because they

package two copies of the RNA genome in virions, which drives

subsequent mixing of sequences during the reverse

transcription process.

Recombination also enables the generation of

replication-competent viruses from defective endogenous

proviruses. Recombination can also extend the viral host range

(cell type and/or host species).

A virus carrying a xenotropic env-gene is more infectious for

human cells as the human XPR1 protein has a preference for

xenotropic murine envelope proteins over polytropic ones.

The replication-competent endogenous cat retrovirus RD-114 is

an example of a recombinant virus expressed from endogenous

sequences. It combines FcEV gag-pol genes (FcEV is an

endogenous retrovirus of cats) and a BaEV env-gene (BaEV is

an endogenous retrovirus of African monkeys) [31].

RD-114 is expressed by all species of the genus Felis, but not

in other felines, and probably originates from a cross-species

transmission of BaEV, followed by a recombination event and

subsequent germ-line integration.

Are mouse-derived biological products the source

of XMRV?

Detection rates of XMRV in populations are extremely variable,

with 0-67% positivity in patients and 0-3.7% in healthy

controls [2-7], suggesting that virus prevalence and thus

exposure could vary significantly with geographic location.

Although the virus could possibly be transmitted from feral

mice to humans in a natural setting, followed by a rapid

dissemination in the human population, the high XMRV

sequence similarity on two continents would suggest an

alternative transmission route.

Likely sources of XMRV are mouse-derived products. Some

mouse genomes encode complete copies of X-MLV's with at

least 92% similarity to XMRV; segments with even higher

homology are present on other locations, and could result in

novel recombinant viruses.

So, X-MLV's that closely resemble XMRV could then be

produced from these loci and virions could be excreted from

mouse tissue or cell cultures.

Are X-MLV's produced in mice?

MLV's, including xenotropic sequences, are actively transcribed

in mouse brain [32], and mice can produce virus particles of

different MLV classes [33]. In vivo recombination between

endogenous and exogenous polytropic MLV's has also been

reported, resulting in viable viral offspring capable of infecting

a variety of species [34].

The Bxv1 locus in M. musculus molossinus is an example of an

endogenous xenotropic/polytropic recombinant MLV that is

expressed and gives rise to a life-long viraemia in laboratory

mice of the F/St strain [23].

Although there was no evidence of X-MLV transmission to

human embryonic stem cells expressing XPR1 after

cocultivation with murine cells expressing X-MLV particles in a

single report [35], this does not imply that transmission may

not have occurred on another occasion.

The prostate carcinoma cell line 22Rv1 is a popular research

tool because it contains approximately 10 integrated copies of

the XMRV provirus and it produces infectious virus [36].

The origin of the 22Rv1 cell line may represent a recent

transmission case as a carcinoma was grafted in nude mice to

establish this permanent cell line [37]. The complete 22Rv1

provirus has 99% sequence similarity with other XMRV isolates

[38].

Possibly, the 22Rv1 carcinoma cells were infected with XMRV

by mouse cells surrounding the tumour graft [36].

Vaccines, viruses and contamination

One of the most widely distributed biological products that

frequently involved mice or mouse tissue, at least up to recent

years, are vaccines, especially vaccines against viruses.

Some, for instance vaccines against rabies virus [39], yellow

fever (YF) virus [40], and Japanese encephalitis (JE) virus [41],

consisted of viruses that were cultured on mouse brains.

Such vaccines were in use from 1931 (YF vaccine) until now

(Japanese encephalitis vaccine, licensed in Japan since 1954).

For rabies virus, early vaccines were mainly of goat or sheep

nerve tissue origin. In addition, suckling mouse brain-derived

rabies virus vaccines were used in South America and France

[39].

No mouse-derived rabies vaccine was ever licensed in the USA

[42]. Live-attenuated YF vaccines were originally also grown

on mouse brain, but an YF vaccine grown on chicken eggs

(named 17D) became available in 1937, and was since the

vaccine of choice in the America's.

In 1962, contamination of the 17D vaccine with oncogenic

avian leukosis virus was detected both in England and in the

USA, but fortunately no excess of cancer incidence among

vaccinees was reported [40]. In France, the mouse-brain

derived YF vaccine was discontinued as late as 1982.

Although being the most effective means to prevent infectious

diseases and to safe lives, serious contamination problems

involving vaccines have occurred [43].

Contamination with unrelated viruses such as the presence of

hepatitis B virus (HBV) in yellow fever vaccine preparations

stemming from the use of human serum for stabilization, and

simian virus 40 (SV40) and foamy viruses through the use of

monkey cell cultures [43].

Some vaccine viruses are inactivated before use, hopefully

also inactivating any contaminating virus particles, but the

contaminating virus may be more stable than the vaccine

virus.

For instance, SV40 is highly resistant to inactivation [44].

Endogenous retroviruses constitute a distinct class of

contaminating viruses, as these viruses are encoded by all

cells of a certain species, and therefore cannot be avoided

even through rigorous screening [45].

Contamination with endogenous avian leukosis viruses is a

major problem for vaccine viruses grown in chicken embryos or

chicken embryonic fibroblasts [46]. Infectious cat endogenous

RD-114 virus has been found in several veterinary vaccines

produced in cat cell cultures [47,48].

XMRV and monoclonal antibodies.

Apart from vaccines, other mouse-derived biologicals could

have been a source of XMRV in the human population.

Monoclonal antibodies present a modern treatment for many

cancers and other diseases including cardiovascular disease,

psoriasis and auto-immune disorders (for a review see: [49]).

The first monoclonal antibody, OKT3 (to be used against

transplant rejection), was approved by the FDA in 1986.

The market for monoclonal antibody therapy has been

expanding rapidly after the year 2000. Initially, murine

antibodies produced by the hybridoma technique were used

[50], but these have been largely abandoned because of

(sometimes severe) allergic reactions.

The murine antibodies were often replaced by humanised

antibodies mainly produced in transgenic mice. Monoclonal

antibodies generated in mice could possibly be polluted by

XMRV and related viruses.

Platinum Taq polymerase from Invitrogen Corporation,

prepared using mouse monoclonal antibodies, is known to be

frequently contaminated with mouse DNA, which can generate

falsepositive PCR amplifications in combination with X-MLV or

XMRV primers [51].

It is less likely that monoclonal antibodies from mice are a

major source of XMRV in the human population as they are in

use only recently, but they could provide a future supply of

mouse-derived viruses.

Although monoclonals are treated with detergents before use

in patients, virus inactivation may not be complete, especially

as protein function should be conserved. And if retroviral

particles containing RNA genomes are copurified with the

antibody proteins, the absence of mouse DNA may give a false

impression of safety.

XMRV contamination of cell lines?

It is possible that XMRV particles were present in virus stocks

cultured in mice or mouse cells for vaccine production, and

that the virus was transferred to the human population by

vaccination.

The sequence homogeneity of all XMRV isolates known today

suggests that only a single or very few transmissions have

occurred, which is consistent with the proposed vaccination

route.

Nowadays, vaccine batches are carefully checked with

sensitive PCR assays for the presence of contaminating

retroviruses, but this screening was not performed in the early

years of vaccination ([52] see also [48]).

Apart from vaccines, other biological products have been

generated using mice or mouse cells. Alternatively, laboratory

contamination with a mouse-derived virus of cell lines used for

e.g. vaccine production could have occurred [53-55]. The virus

could then unintentionally have been transmitted to the

human population.

Nowadays, many vaccine strains are grown in human diploid

cell lines [56], which are susceptible to MLV infection. A recent

report detected other MLV-related sequences in CFS patients

and healthy controls from North America [57], suggesting that

more MLV strains may have been transmitted to the human

population, possibly in a similar fashion.

However, solid evidence that these polytropic MLV sequences

represent replicating virus is currently lacking.

Where was XMRV transmitted?

XMRV was found in samples from CFS patients in North

America, but not in Europe. The virus was detected in prostate

cancer tissue from patients on both continents. There is a

single report with negative results from China [58], and a

single report with one positive sample from Mexico [59] but

none from other areas of the world, leaving many questions

about the true distribution of XMRV in humans.

Prevalence of XMRV from North American studies varies

between 3.7-67% in four studies with two other studies

reporting negative results (one in CFS patients and healthy

controls [6], and one in HIV-infected patients receiving

antiretroviral therapy and untreated men at risk for HIV

infection [60]).

In Europe, XMRV was detected in two studies from Germany

[3], and in one from The Netherlands [61], but not in the

United Kingdom [5,62], France [63], Denmark [64], and two

other studies from The Netherlands [7,65], although the

nature of the samples analysed differed between studies.

Table 1 summarizes the results from these studies.

XMRV sequences from Germany and North America exhibit very

little nucleotide divergence, suggesting that they descended

from a common ancestor relatively recently.

A close inspection of the phylogenetic trees obtained with

XMRV-gag sequences [3,4] suggests that XMRV sequences

from the USA are closer to the common ancestor than German

XMRV sequences, although the trees are not optimal due to

the high sequence conservation.

Being closer to the most recent common ancestor (MRCA) is

suggestive of an older virus. Possibly, XMRV was transmitted

from mice to men in the USA, and soon after this event

introduced into Germany.

Germany had close connections with the USA after World War

II, with large numbers of military personnel (and their

families) stationed in Germany from 1945 till present times.

In 2006, there were still 57.080 American army employees

distributed over more than 200 locations in Germany, mainly in

the south and west of the country

(www.defense.gov/pubs/BSR_2007_Baseline.pdf).

US military personnel are highly vaccinated, e.g. virtually all

recruits were vaccinated with YF vaccine in 1941- 1942 after

the outbreak of World War II [40].

A massive outbreak of jaundice, with at least 26,000 cases in

the Western region of the USA, was due to the use of human

serum contaminated with HBV in the vaccine (see [40]).

Recently, massive smallpox vaccination of the US army

personnel has been carried out [66]. XMRV infected Americans

could subsequently have introduced the virus into Germany.

Spread of XMRV

The combined results suggest (1) that XMRV was recently

transmitted from mice to humans, either from a single source,

or at least from a single (sub) species of mice, and (2) that all

XMRV-positive individuals known today were infected with this

newly-emerged virus only recently, as a very high sequence

identity is normally only seen after a direct retrovirus

transmission.

Whatever the mechanism of XMRV cross-species transmission

from mouse in humans, the possible spread from human to

human forms a major health threat.

Sexual transmission was initially proposed [67], but XMRV was

not detected in seminal plasma from HIV- infected men [65].

The detection of XMRV fragments in the respiratory tract [3]

suggests that the virus may be transmitted by saliva, although

RNA concentrations were low. Transmission through saliva,

mainly by biting, has been reported for most retrovirus genera,

including ecotropic MLV's [68].

Another major threat is transmission through blood products

as infectious virus has been cultured from blood cells [2].

Up till now, all patients with detectable XMRV have been

adults, the majority of them middle-aged or older (mean ± 55

years).

A study in 142 children with a diversity of pathologies,

including respiratory diseases in France revealed no XMRV

infections in that age group [63], although the incidence of

XMRV in France is not known.

Another study in autistic children from the USA and Italy was

also negative for XMRV [69].

XMRV can likely be acquired at any age, and then probably

establishes a chronic, latent infection like other retroviruses.

Therefore the age of XMRV-infected individuals does not

provide an unambiguous clue about when XMRV entered the

human population.

Conclusion

In conclusion, the most likely mode of XMRV transmission

points to mouse-derived biological products, but it cannot

formally be excluded that the virus was once transferred from

feral mice to humans.

The latter scenario is less likely as it would imply that a very

rapid spread in the human population must have occurred to

explain its presence on two continents. In this scenario, the

extreme sequence similarity among XMRV genomes, both

between and within individuals, would argue that the virus

replicates at very low levels.

Among the biological products, vaccines that were produced in

mice or mouse cells are possible candidates that warrant

further inspection. If XMRV was introduced in the human

population through the use of biologicals, a background level

of the virus in the human population, possibly varying with

geography or age group, would be expected.

Such a low level presence would then also explain the

(absence of) detection of the virus in different studies, as

well as its controversial association with disease.

We hope that this hypothesis will spur further discussion and

help to resolve the many remaining XMRV questions.

Acknowledgement

We thank Hans Zaaijer for insightful discussions and

proofreading of the manuscript.

References

1. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G,

Klein EA, Malathi K, Magi- Galluzzi C, Tubbs RR, Ganem D,

Silverman RH, DeRisi JL: Identification of a novel

Gammaretrovirus in prostate tumors of patients homozygous

for R462Q RNASEL variant. PLoS Pathog 2006, 2:e25.

2. Lombardi VC, Ruscetti FW, Das GJ, Pfost MA, Hagen KS,

DL, Ruscetti SK, Bagni RK, Petrow-Sadowski C, Gold

B, Dean M, Silverman RH, Mikovits JA: Detection of an

infectious retrovirus, XMRV, in blood cells of patients with

chronic fatigue syndrome. Science 2009, 326:585-589.

3. Fischer N, Schulz C, Stieler K, Hohn O, Lange C, Drosten C,

Aepfelbacher M: Xenotropic murine leukemia virus-related

gammaretrovirus in respiratory tract. Emerg Infect Dis 2010,

16:1000-1002.

4. Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H,

Aepfelbacher M, Schlomm T: Prevalence of human

gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol

2008, 43:277-283.

5. Groom HC, Yap MW, Galao RP, Neil SJ, Bishop KN:

Susceptibility of xenotropic murine leukemia virus-related virus

(XMRV) to retroviral restriction factors. Proc Natl Acad Sci USA

2010, 107:5166-5177.

6. Switzer WM, Jia H, Hohn O, Zheng H, Tang S, Shankar A,

Bannert N, G, Hendry RM, Falkenberg VR, Reeves

WC, Heneine W: Absence of evidence of Xenotropic Murine

Leukemia Virus-related virus infection in persons with Chronic

Fatigue Syndrome and healthy controls in the United States.

Retrovirology 2010, 7:57.

7. van Kuppeveld FJ, de Jong AS, Lanke KH, Verhaegh GW,

Melchers WJ, Swanink CM, Bleijenberg G, Netea MG, Galama

JM, van der Meer JW: Prevalence of xenotropic murine

leukaemia virus-related virus in patients with chronic fatigue

syndrome in the Netherlands: retrospective analysis of

samples from an established cohort. BMJ 2010, 340:c1018.

8. Sharma P, Suppiah S, Molinaro R, K, Das Gupta J,

Silverman R, Hackett Jr J, Devare S, Schochetman G, Villinger

F: Organ and Cell Lineage Dissemination of XMRV in Rhesus

Macaques during Acute and Chronic Infection [abstract]. CROI,

San Francisco, February 16-19 2010, Paper #150LB

9. Silverman RH, Nguyen C, Weight CJ, Klein EA: The human

retrovirus XMRV in prostate cancer and chronic fatigue

syndrome. Nat Rev Urol 2010, 7:392-402.

10. Coffin JM, Stoye JP: Virology. A new virus for old diseases?

Science 2009, 326:530-531.

11. Kearney M, Maldarelli F: Current Status of Xenotropic

Murine Leukemia Virus- Related Retrovirus in Chronic Fatigue

Syndrome and Prostate Cancer: Reach for a Scorecard, Not a

Prescription Pad. J Infect Dis 2010, 202:1463-1466.

12. Kaiser J: Virology. No meeting of minds on XMRV's role in

chronic fatigue, cancer. Science 2010, 329:1454.

13. Weiss RA: A cautionary tale of virus and disease. BMC Biol

2010, 8:124.

14. Stieler K, Schulz C, Lavanya M, Aepfelbacher M, Stocking C,

Fischer N: Host range and cellular tropism of the human

exogenous gammaretrovirus XMRV. Virology 2010, 399:23-30.

15. Dong B, Kim S, Hong S, Das GJ, Malathi K, Klein EA,

Ganem D, DeRisi JL, Chow SA, Silverman RH: An infectious

retrovirus susceptible to an IFN antiviral pathway from human

prostate tumors. Proc Natl Acad Sci U S A 2007,

104:1655-1660.

16. Kim S, Kim N, Dong B, Boren D, Lee SA, Das GJ, Gaughan

C, Klein EA, Lee C, Silverman RH, Chow SA: Integration site

preference of xenotropic murine leukemia virus-related virus, a

new human retrovirus associated with prostate cancer. J Virol

2008, 82:9964-9977.

17. Klein SL, Calisher CH: Emergence and persistence of

hantaviruses. Curr Top Microbiol Immunol 2007, 315:217-252.

18. Charrel RN, de Lamballerie X: Zoonotic aspects of

arenavirus infections. Vet Microbiol 2010, 140:213-220.

19. Hart CA, M: Hantavirus infections: epidemiology

and pathogenesis. Microbes Infect 1999, 1:1229-1237.

20. Tailor CS, Nouri A, Lee CG, Kozak C, Kabat D: Cloning and

characterization of a cell surface receptor for xenotropic and

polytropic murine leukemia viruses. Proc Natl Acad Sci USA

1999, 96:927-932.

21. Yang H, Bell TA, Churchill GA, Pardo- d, V: On the

subspecific origin of the laboratory mouse. Nat Genet 2007,

39:1100-1107.

22. Marin M, Tailor CS, Nouri A, Kozak SL, Kabat D:

Polymorphisms of the cell surface receptor control mouse

susceptibilities to xenotropic and polytropic leukemia viruses. J

Virol 1999, 73:9362-9368.

23. Baliji S, Liu Q, Kozak CA: Common inbred strains of the

laboratory mouse that are susceptible to infection by mouse

xenotropic gammaretroviruses and the human derived XMRV. J

Virol 2010, in press.

24. Battini JL, Rasko JE, AD: A human cell-surface

receptor for xenotropic and polytropic murine leukemia viruses:

possible role in G protein-coupled signal transduction. Proc

Natl Acad Sci USA 1999, 96:1385-1390.

25. Yan Y, Liu Q, Wollenberg K, C, Buckler-White A,

Kozak CA: Evolution of functional and sequence variants of the

mammalian XPR1 receptor for mouse xenotropic

gammaretroviruses and the human-derived XMRV. J Virol 2010,

in press.

26. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R:

Viral mutation rates. J Virol 2010, 84:9733-9748.

27. Switzer WM, Bhullar V, Shanmugam V, Cong ME, Parekh B,

Lerche NW, Yee JL, Ely JJ, Boneva R, Chapman LE, Folks TM,

Heneine W: Frequent simian foamy virus infection in persons

occupationally exposed to nonhuman primates. J Virol 2004,

78:2780-2789.

28. Liu W, Worobey M, Li Y, Keele BF, Bibollet-Ruche F, Guo Y,

Goepfert PA, Santiago ML, Ndjango JB, Neel C, Clifford SL,

Sanz C, Kamenya S, ML, Pusey AE, Gross-Camp N,

Boesch C, V, Zamma K, Huffman MA, Mitani JC, Watts

DP, Peeters M, Shaw GM, Switzer WM, Sharp PM, Hahn BH:

Molecular ecology and natural history of simian foamy virus

infection in wild-living chimpanzees. PLoS Pathog 2008,

4:e1000097.

29. Calattini S, Wanert F, Thierry B, Schmitt C, Bassot S, Saib

A, Herrenschmidt N, Gessain A: Modes of transmission and

genetic diversity of foamy viruses in a Macaca tonkeana

colony. Retrovirology 2006, 3:23.

30. Courgnaud V, Battini JL, Sitbon M, Mason AL: Mouse

retroviruses and chronic fatigue syndrome: Does X (or P) mark

the spot? Proc Natl Acad Sci USA 2010.

31. van der Kuyl AC, Dekker JT, Goudsmit J: Discovery of a

new endogenous type C retrovirus (FcEV) in cats: evidence for

RD-114 being an FcEV(Gag-Pol)/baboon endogenous virus

BaEV(Env) recombinant. J Virol 1999, 73:7994-8002.

32. Kwon DN, Nguyen S, Chew A, Hsu K, Greenhalgh D, Cho K:

Identification of putative endogenous retroviruses actively

transcribed in the brain. Virus Genes 2008, 36:439- 447.

33. Ribet D, Harper F, Esnault C, Pierron G, Heidmann T: The

GLN family of murine endogenous retroviruses contains an

element competent for infectious viral particle formation. J

Virol 2008, 82:4413-4419.

34. LH, Alamgir AS, Owens N, Weber N, Virtaneva K,

Barbian K, Babar A, Malik F, Rosenke K: Mobilization of

endogenous retroviruses in mice after infection with an

exogenous retrovirus. J Virol 2009, 83:2429-2435.

35. Amit M, Winkler ME, Menke S, Bruning E, Buscher K,

Denner J, Haverich A, Itskovitz- Eldor J, U: No evidence

for infection of human embryonic stem cells by feeder

cell-derived murine leukemia viruses. Stem Cells 2005,

23:761-771.

36. Knouf EC, Metzger MJ, PS, Arroyo JD, Chevillet JR,

Tewari M, AD: Multiple integrated copies and high-level

production of the human retrovirus XMRV (xenotropic murine

leukemia virus-related virus) from 22Rv1 prostate carcinoma

cells. J Virol 2009, 83:7353-7356.

37. Sramkoski RM, Pretlow TG, Giaconia JM, Pretlow TP,

Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, berger

JW: A new human prostate carcinoma cell line, 22Rv1. In Vitro

Cell Dev Biol Anim 1999, 35:403-409.

38. Paprotka T, Venkatachari NJ, Chaipan C, Burdick R,

Delviks-enberry KA, Hu WS, Pathak VK: Inhibition of

xenotropic murine leukemia virus-related virus by APOBEC3

proteins and antiviral drugs. J Virol 2010, 84:5719-5729.

39. Plotkin SA, Wiktor T: Rabies vaccination. Annu Rev Med

1978, 29:583-591.

40. Frierson JG: The yellow fever vaccine: a history. Yale J Biol

Med 2010, 83:77-85.

41. Inactivated Japanese encephalitis virus vaccine.

Recommendations of the Advisory Committee on Immunization

Practices (ACIP). MMWR Recomm Rep 1993, 42:1-15.

42. PH: Active immunization in the United States:

developments over the past decade. Clin Microbiol Rev 2001,

14:872-908, table.

43. Pastoret PP: Human and animal vaccine contaminations.

Biologicals 2010, 38:332-334.

44. Murray R: Biologicals for the control and therapy of virus

diseases. Bacteriol Rev 1964, 28:493-496.

45. Miyazawa T: Endogenous retroviruses as potential hazards

for vaccines. Biologicals 2010, 38:371-376.

46. Hussain AI, JA, Da Silva FM, Heneine W:

Identification and characterization of avian retroviruses in

chicken embryo-derived yellow fever vaccines: investigation of

transmission to vaccine recipients. J Virol 2003, 77:1105-1111.

47. Yoshikawa R, Sato E, Igarashi T, Miyazawa T:

Characterization of RD-114 Virus Isolated from a Commercial

Canine Vaccine Manufactured Using CRFK Cells. J Clin Microbiol

2010, 48:3366-3369.

48. Miyazawa T, Yoshikawa R, Golder M, Okada M, H,

Palmarini M: Isolation of an infectious endogenous retrovirus

in a proportion of live attenuated vaccines for pets. J Virol

2010, 84:3690-3694.

49. Stern M, Herrmann R: Overview of monoclonal antibodies

in cancer therapy: present and promise. Crit Rev Oncol

Hematol 2005, 54:11-29.

50. Kohler G, Milstein C: Continuous cultures of fused cells

secreting antibody of predefined specificity. Nature 1975,

256:495-497.

51. Erlwein O, Kaye S, M, McClure M: Chronic fatigue

syndrome: Xenotropic murine leukemia virus-related virus,

murine leukemia virus, both, or neither? Proc Natl Acad Sci U S

A 2010, in press.

52. Trijzelaar B: Regulatory affairs and biotechnology in

Europe: III. Introduction into good regulatory

practice--validation of virus removal and inactivation.

Biotherapy 1993, 6:93-102.

53. Hartley JW, LH, Green KY, Naghashfar Z, Macias AR,

Zerfas PM, Ward JM: Expression of infectious murine leukemia

viruses by RAW264.7 cells, a potential complication for studies

with a widely used mouse macrophage cell line. Retrovirology

2008, 5:1.

54. Takeuchi Y, McClure MO, Pizzato M: Identification of

gammaretroviruses constitutively released from cell lines used

for human immunodeficiency virus research. J Virol 2008,

82:12585-12588.

55. Stang A, Petrasch-Parwez E, Brandt S, Dermietzel R, Meyer

HE, Stuhler K, Liffers ST, Uberla K, Grunwald T: Unintended

spread of a biosafety level 2 recombinant retrovirus.

Retrovirology 2009, 6:86.

56. Fletcher MA, Hessel L, Plotkin SA: Human diploid cell

strains (HDCS) viral vaccines. Dev Biol Stand 1998, 93:97-107.

57. Lo SC, Pripuzova N, Li B, Komaroff AL, Hung GC, Wang R,

Alter HJ: Detection of MLVrelated virus gene sequences in

blood of patients with chronic fatigue syndrome and healthy

blood donors. Proc Natl Acad Sci USA 2010.

58. Hong P, Li J, Li Y: Failure to detect xenotropic murine

leukaemia virus-related virus in Chinese patients with chronic

fatigue syndrome. Virol J 2010, 7:224.

59. ez-Fierro ML, Leach RJ, Gomez-Guerra LS,

Garza-Guajardo R, -Pais T, Beuten J,

Morales- IB, -Ordonez MA,

Calderon-Cardenas G, Ortiz- R, Rivas-Estilla AM,

ncer- J, Rojas-ez A: Identification of viral

infections in the prostate and evaluation of their association

with cancer. BMC Cancer 2010, 10:326.

60. Kunstman KJ, Bhattacharya T, Flaherty J, Phair JP,

Wolinsky SM: Absence of xenotropic murine leukemia

virus-related virus in blood cells of men at risk for and infected

with HIV. AIDS 2010, 24:1784-1785.

61. Verhaegh GW, de Jong AS, Smit FP, Jannink SA, Melchers

WJ, Schalken JA: Prevalence of human xenotropic murine

leukemia virus-related gammaretrovirus (XMRV) in dutch

prostate cancer patients. Prostate 2010, in press.

62. Erlwein O, Kaye S, McClure MO, Weber J, Wills G, Collier D,

Wessely S, Cleare A: Failure to detect the novel retrovirus

XMRV in chronic fatigue syndrome. PLoS ONE 2010, 5:e8519.

63. Jeziorski E, Foulongne V, Ludwig C, Louhaem D, Chiocchia

G, Segondy M, Rodiere M, Sitbon M, Courgnaud V: No evidence

for XMRV association in pediatric idiopathic diseases in France.

Retrovirology 2010, 7:63.

64. Maric R, Pedersen FS, Kjeldbjerg A, Moeller-Larsen A,

Bahrami S, Brudek T, sen T, Christensen T: Absence of

xenotropic murine leukaemia virus-related virus in Danish

patients with multiple sclerosis. J Clin Virol 2010, 49:227-228.

65. Cornelissen M, Zorgdrager F, Blom P, Jurriaans S, Repping

S, van LE, Bakker M, Berkhout B, van der Kuyl AC: Lack of

detection of XMRV in seminal plasma from HIV-1 infected men

in The Netherlands. PLoS ONE 2010, 5:e12040.

66. Grabenstein JD, Winkenwerder W, Jr.: US military smallpox

vaccination program experience. JAMA 2003, 289:3278-3282.

67. Hong S, Klein EA, Das GJ, Hanke K, Weight CJ, Nguyen C,

Gaughan C, Kim KA, Bannert N, Kirchhoff F, Munch J, Silverman

RH: Fibrils of prostatic acid phosphatase fragments boost

infections with XMRV (xenotropic murine leukemia virus-related

virus), a human retrovirus associated with prostate cancer. J

Virol 2009, 83:6995-7003.

68. Portis JL, McAtee FJ, SF: Horizontal transmission of

murine retroviruses. J Virol 1987, 61:1037-1044.

69. Satterfield BC, RA, Gurrieri F, Schwartz CE: PCR and

serology find no association between xenotropic murine

leukemia virus-related virus (XMRV) and autism. Mol Autism

2010, 1:14.

70. Arnold RS, Makarova NV, Osunkoya AO, Suppiah S,

TA, NA, Bhosle SM, Liotta D, Hunter E, Marshall FF, Ly

H, Molinaro RJ, Blackwell JL, Petros JA: XMRV infection in

patients with prostate cancer: novel serologic assay and

correlation with PCR and FISH. Urology 2010, 75:755-761.

71. Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM,

Isaacs WB: A molecular analysis of prokaryotic and viral DNA

sequences in prostate tissue from patients with prostate

cancer indicates the presence of multiple and diverse

microorganisms. Prostate 2008, 68:306-320.

72. son BP, Ayala GE, Kimata JT: Detection of

Xenotropic Murine Leukemia Virus Related Virus in Normal and

Tumor Tissue of Patients from the Southern United States with

Prostate Cancer Is Dependent on Specific Polymerase Chain

Reaction Conditions. J Infect Dis 2010, 202:1470-1477.

73. Henrich TJ, Li JZ, Felsenstein D, Kotton CN, Plenge RM,

Pereyra F, Marty FM, Lin NH, Grazioso P, Crochiere DM, Eggers

D, Kuritzkes DR, Tsibris AMN: Xenotropic Murine Leukemia

Virus Related Virus Prevalence in Patients with Chronic Fatigue

Syndrome or Chronic Immunomodulatory Conditions. J Infect

Dis 2010, 202:1478-1481.

74. E, Flanagan P, Brown A, N, Brown H,

McClure M, Oxenius A, Collier J, Weber J, fc Nthard HX,

Hirschel B, Fidler S, R, Frater J: Failure to Detect

Xenotropic Murine Leukemia Virus Related Virus in Blood of

Individuals at High Risk of Blood Borne Viral Infections. J

Infect Dis 2010, 202:1482-1485.

Join the conversation

You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.

Guest
Reply to this topic...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

Loading...
×
×
  • Create New...